GPCR 3D modeling

doi:10.1017/CBO9780511730412.018

16 - GPCR 3D modeling

from PART III - APPLICATIONS TO DRUG DISCOVERY

Published online by Cambridge University Press: 06 July 2010

Frank U. Axe

Edited by

Kenneth M. Merz, Jr ,

Dagmar Ringe and

Charles H. Reynolds

Show author details

Kenneth M. Merz, Jr: Affiliation:
University of Florida
Dagmar Ringe: Affiliation:
Brandeis University, Massachusetts
Charles H. Reynolds: Affiliation:
Johnson & Johnson Pharmaceutical Research & Development

Book contents

Get access

Summary

INTRODUCTION

G-protein-coupled receptors (GPCRs) are a superfamily of membrane proteins that provide cells with the ability to communicate with each other and their environment. The core feature of these proteins is their seven transmembrane helices (7TM) that form a bundle located in the cell membrane (Figure 16.1). The seven helices are linked together by three extracellular loops (ECLs) and three intracellular loops (ICLs) and also include N- and C-terminal regions. This 7TM region is responsible for receiving a wide range of signals from small-molecule amines, peptides, proteins, small odorant and taste molecules, and light, which either bind in the interior of the 7TM bundle or to its extracellular surface or interact with chromophores located in its interior. These external signals trigger the coupling of the ICLs (in particular ICL5) with the heterotrimeric G-protein transducin, which in turn initiates a cascade of signaling events that lead to proliferation, differentiation, development, cell survival, angiogenesis, and hypertrophy. In light of these facts it is not surprising to find that GPCRs are implicated as targets in a wide range of indications, including heart disease, allergies, depression, mental illness, cognition, and hypertension.

The estimated number of GPCRs in humans is ∼1,000 members or ∼1% of the genome. There are five major classes of GPCRs that are defined by their sequence homology and the type of endogenous ligand. The most important of these classes are A, B, and C. GPCRs are dysfunctional or dysregulated in many diseases making them the target of drug therapies.

Type: Chapter
Information: Drug Design
Structure- and Ligand-Based Approaches
, pp. 248 - 256

DOI: https://doi.org/10.1017/CBO9780511730412.018 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Filmore, D.It's a GPCR worldMod. Drug Discov. 2004, 7, 47–48.Google Scholar

Bockaert, J.; Pin, J. P.Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 18, 1723.Google Scholar

Wise, A.; Gearing, K.; Rees, S.Target validation of G-protein coupled receptors. Drug Discov. Today 2002, 7, 235.Google Scholar

Leach, A. R.Molecular Modeling Principles and Applications. Essex, UK: Prentice Hall; 2001.

Müller, G. Towards 3D Structures of G Protein-Coupled Receptors: A Multidisciplinary Approach. Curr. Med. Chem. 2000, 7, 861.Google Scholar

Bleicher, K. H.; Green, L. G.; Martin, R. E.; Rogers-Evans, M.Ligand identification for G-protein-coupled receptors: a lead generation perspective. Curr. Opin. Chem. Biol. 2004, 8, 287.Google Scholar

Walters, W. P.; Stahl, M. T.; Murcko, M. A.Virtual screening – an overview. Drug Discov. Today 1998, 3, 160.Google Scholar

Hawkins, P. C. D.; Skillman, A.G.; Nicholls, A.Comparison of Shape-Matching and Docking as Virtual Screening Tools. J. Med. Chem. 2007, 50, 74.Google Scholar

Clement, O.; Mehl, A.T. In: Pharmacophore Preception, Development, and Use in Drug Design, Guner, O. F., Ed.; La Jolla, CA: International University Line; 2000, 71.

Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M.Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739.Google Scholar

Stenkamp, R. E.; Teller, D. C.; Palczewski, K.Crystal Structure of Rhodopsin: A G-Protein-Coupled Receptor. ChemBioChem 2002, 3, 963.Google Scholar

Rasmussen, S. G. F.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, B. K.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R. P.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F. X.; Weis, W. I.; Kobilka, T. S.Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 2007, 450, 383.Google Scholar

Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C.High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor. Science 2007, 318, 1258.Google Scholar

Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K.GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function. Science 2007, 318, 1266.Google Scholar

Greer, J.Comparative modeling methods: application to the family of the mammalian serine proteases. Proteins 1990, 7, 317.Google Scholar

Lanyi, J.; Luecke, H.Bacteriorhodopsin. Curr. Opin. Struc. Biol. 2001, 11, 415.Google Scholar

Lanyi, J. K.Bacteriorhodopsin. Annu. Rev. Physiol. 2004, 66 665.Google Scholar

Pebay-Peyroula, E.; Rummel, G.; Rosenbusch, J. P; Landau, E. M.X-ray Structure of Bacteriorhodopsin at 2.5 Angstroms from Microcrystals Grown in Lipidic Cubic Phases. Science, 1997, 277, 1676.Google Scholar

Luecke, H.; Richter, H. T.; Lanyi, J. K.Proton transfer pathways in bacteriorhodopsin at 2.3 angstrom resolution. Science, 1998, 280, 1934.Google Scholar

Luecke, H.; Schobert, B.; Richter, H. T.; Cartailler, J. P.; Lanyi, J. K.Structure of Bacteriorhodopsin at 1.55 Å Resolution. J. Mol. Biol., 1999, 291, 899.Google Scholar

Baldwin, J. M.The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993, 12 1693.Google Scholar

Unger, V. M.; Schertler, G. F. X.Low resolution structure of bovine rhodopsin determined by electron cryo-microscopy. Biophys. J. 1995, 68, 1776.Google Scholar

Schertler, G. F.; Villa, C.; Henderson, R.Projection structure of rhodopsin. Nature 1993, 362, 770.Google Scholar

Pardo, L.; Ballesteros, J. A.; Osman, R.; Weinstein, H.On the use of the transmembrane domain of bacteriorhodopsin as a template for modeling the three-dimensional structure of guanine nucleotide-binding regulatory protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4009.Google Scholar

Hibert, M. F.; Trumpp-Kallmeyer, S.; Bruinvels, A.; Hofloack, J.Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 1991, 40, 8.Google Scholar

MaloneyHuss, K.; Lybrand, T. P.Three-dimensional structure for the β2 adrenergic receptor protein based on computer modeling studies. J. Mol. Biol. 1992, 225, 859.Google Scholar

Alorta, I.; Loew, G. H.A 3D model of the ö opioid receptor and ligand-receptor complexes. Protein Eng. 1996, 9, 573.Google Scholar

Archer, E.; Maigret, B.; Escrieut, C.; Pradayrol, L.; Fourmy, D.Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors?Trends Pharmacol. Sci. 2003, 24, 36.Google Scholar

Hubbell, W. L.; Altenbach, C.; Hubbell, C. M.; Khorana, H.G.Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 2003, 63, 243.Google Scholar

Kobilka, B.; Schertler, F. X.New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol. Sci. 2008, 29, 79.Google Scholar

Oliveira, L.; Hulsen, T.; Lutje Hulsik, D.; Paiva, A. C.; Vriend, G.Heavier-than-air flying machines are impossible. FEBS Lett. 2004 564, 269.Google Scholar

Hibert, M. F.Protein homology modeling and drug discovery. In: The Practice of Medicinal Chemistry. New York, NY: Academic Press; 1996, 523–546.

Kiss, R.; Koᾓri, Z.; Keserũ, G. M.Homology modeling and binding site mapping of the human histamine H1 receptor Eur. J. Med. Chem. 2004, 39, 959.Google Scholar

Furse, K. E.; Lybrand, T. P.Three-Dimensional Models for β-Adrenergic Receptor Complexes with Agonists and Antagonists. J. Med. Chem. 2003, 46, 4450.Google Scholar

Evers, A; Klabunde, T. Structure-based Drug Discovery Using GPCR Homology Modeling: Successful Virtual Screening for Antagonists of the Alpha1A Adrenergic Receptor. J. Med. Chem. 2005, 48, 1088.Google Scholar

Axe, F. U.; Bembenek, S. D.; Szalma, S.Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. J. Mol. Graph. Model. 2006, 24, 456.Google Scholar

Costanzi, S. On the Applicability of GPCR Homolgy Models to Computer-Aided Drug Discovery: A Comparison between In Silico and Crystal Structures of the β2-Adrenergic Receptor. J. Med. Chem. 2008, 51, 2907.Google Scholar

Becker, O. M.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; Warshaviak, D.; Fichman, M.; Noiman, S.G Protein-coupled receptors: In silico drug discovery in 3D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11304.Google Scholar

Shacham, S.; Marantz, Y.; Bar-Haim, S.; Kalid, O.; Warshaviak, D.; Avisar, N.; Inbal, B.; Heifetz, A.; Fichman, M.; Topf, M.; Naor, Z.; Noiman, S.; Becker, O.M.PREDICT Modeling and In-Silico Screening for G-Protein Coupled Receptors. Proteins 2004, 57, 51.Google Scholar

Vaidehi, N.; Floriano, W. B.; Trabanino, R.; Hall, S. E.; Freddolino, P.; Choi, E. J.; Zamanakos, G.; Goddard, W. A.Prediction of structure and function of G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12627.Google Scholar

Floriano, W. B.; Vaidehi, N.; Goddard, W. A.; Singer, M. S.; Shepherd, G. M.Molecular mechanisms underlying differential odor responses of a mouse olfactory receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 10712.Google Scholar

Li, Y.; Goddard, W. A.Prediction of the Structure of G-Protein Coupled Receptor with Application for Drug Design. Pac. Symp. Biocomput. 2008, 13, 344.Google Scholar

Kontoyianni, M.; DeWeese, C.; Penzotti, J. E.; Lybrand, T. P.Three-Dimensional Models for Agonist and Antagonist Complexes with β2 Agrenergic Receptor. J. Med. Chem. 1996, 4406.Google Scholar

Xhaard, H.; Rantanen, V. V.; Nyrönen, T.; Johnson, M. S.Molecular Evolution of Adrenoceptors and Dopamine Receptors: Implications for the Binding of Catecholamines. J. Med. Chem. 2006, 49, 1706.Google Scholar

Trumpp-Kallmeyer, S.; Hoflack, J.; Bruinvels, A.; Hibert, M.Modeling of G-Protein-Coupled Receptors: Application to Dopamine, Adrenaline, Serotonin, Acetylcholine, and Mammalian Opsin Receptors. J. Med. Chem. 1992, 35, 3448.Google Scholar

Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D.Protein-Based Virtual Screening of Chemical Databases. II. Are Homology Models of G-Protein Coupled Receptors Suitable Targets?Proteins 2003, 50, 5.Google Scholar

Cavasotto, C. N.; Orry, A. J. W.; Murgolo, N. J.; Czarniecki, M. F.; Kocsi, S. A.; Hawes, B. E.; O'Neill, K. A.; Hine, H.; Burton, M. S.; Voigt, J. H.; Abagyan, R. A.; Bayne, M. L.; Monsma, F. J.Discovery of Novel Chemotypes to a G-Protein-Coupled Receptor through Ligand-Steered Homology Modeling and Structure-Based Virtual Screening. J. Med. Chem. 2008, 51, 581.Google Scholar

Kiss, R.; Kiss, B.; Könczöl, A.; Szalai, F.; Jelinek, I.; László, V.; Noszál, B.; Falus, A.; Keserũ, G. M.Discovery of Novel Human Histamine H4 Receptor Ligands by Large-Scale Structure-Based Virtual Screening. J. Med. Chem. 2008, 51, 3145.Google Scholar

Cavasotto, C. N.; Orry, A. J. W.; Abagyan, R. A.Structure-Based Identification of Binding Sites, Native Ligands and Potential Inhibitors for G-Protein Coupled Receptors. Proteins 2008, 51, 423.Google Scholar

Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Levant, B.; Wang, S.Molecular Modeling of the Three-Dimensional Structure of Dopamine 3 (D3) Subtype Receptor: Discovery of Novel and Potent D3 Ligands through a Hybrid Pharmacophore- and Structure-Based Database Screening Approach. J. Med. Chem. 2003, 46, 4377.Google Scholar

Kellenberger, E.; Springael, J. Y.; Parmentier, M.; Hachet-Haas, M.; Galzi, J. L.; Rognan, D.Identification of Nonpeptide CCR5 Receptor Agonists by Structure-based Virtual Screening. J. Med. Chem. 2007, 50, 1294.Google Scholar

Topiol, S.; Sabio, M.Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. Bioorg. Med. Chem. Lett. 2008, 18, 1598.Google Scholar

Crozier, P. S.; Stevens, M. J.; Forrest, L. R.; Woolf, T. B.Molecular Dynamics Simulation of Dark-adapted Rhodopsin in an Explicit Membrane Bilayer: Coupling between Local Retinal and Larger Scale Conformational Change. J. Mol. Biol. 2003, 333, 493.Google Scholar

Spijker, P.; Vaidehi, N.; Freddolino, P. L.; Hilbers, P. A.; Goddard, W. A.Dynamic behavior of fully solvated β2-adrenergic receptor, embedded in the membrane with bound agonist or antagonist. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4882.Google Scholar

Henin, J.; Maigret, B.; Tarek, M.; Escrieut, C.; Fourmy, D.; Chipot, C.Probing a Model of a GPCR/Ligand Complex in an Explicit Membrane Environment: The Human Cholecystokinin-1 Receptor. Biophys. J. 2006, 90, 1232.Google Scholar

Trent, J. O.; Wang, Z.; Murray, J. L.; Shao, W.; Tamamura, H.; Fuji, N.; Peiper, S. C.Lipid Bilayer Simulations of CXCR4 with Inverse Agonists and Weak Partial Agonists. J. Biol. Chem. 2003, 278, 47136.Google Scholar

Spassov, V.; Yan, L.; Szalma, S.Introducing an Implicit Membrane in Generalized Born/Solvent Accessibility Continuum Solvent Models. J. Phys. Chem. B 2002, 106, 8726.Google Scholar

Im, W.; Feig, M.; Brooks, C. L.An Implicit Membrane Generalized Born Theory for the Study of Structure, Stability, and Interactions of Membrane Proteins. Biophys. J. 2003, 85, 2900.Google Scholar

Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T.Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127.Google Scholar

Gouldson, P. R.; Kidley, N. J.; Bywater, R. P.; Psaroudakis, G.; Brooks, H.D.; Diaz, C.; Shire, D.; Reynolds, C.A.Toward the Active Conformations of Rhodopsin and the β2-Adrenergic Receptor. Proteins 2004, 56, 67.Google Scholar

Niv, M. Y.; Skrabanek, L.; Filizola, M.; Weinstein, H.Modeling activated states of GPCRs: the rhodopsin template. J. Comput. Aided Mol. Des. 2006, 20, 437.Google Scholar

Salom, D.; Lodowski, D. T.; Stenkamp, R. E.; Trong, I.; Golczak, M.; Jastrzebska, B.; Harris, T.; Ballesteros, J. A.; Palczewski, K.Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16123.Google Scholar

Erlanson, D. A.; Wells, J. A.; Braisted, A. C.TETHERING: Fragment-Based Drug Discovery. Annu. Rev. Biophys. Struct. 2004, 33, 199.Google Scholar

Zartler, E. R.; Shapiro, M. J.Fragonomics: fragment-based drug discovery. Curr. Opin. Chem. Biol. 2005, 9, 366.Google Scholar

Book contents

16 - GPCR 3D modeling

Summary

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive